Home World News FDA Approves Vimseltinib for Symptomatic Tenosynovial Giant Cell Tumour World News FDA Approves Vimseltinib for Symptomatic Tenosynovial Giant Cell Tumour By Ogkologos - April 4, 2025 896 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MOTION study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Tarlatamab Prolongs OS Over Chemotherapy Among Patients with SCLC Whose Disease... June 16, 2025 10 Things I Wish I Knew When I Was First Diagnosed... July 19, 2022 Researchers Have Discovered How Fat Cells Fuel The Spread Of Breast... December 19, 2019 Combining Enzalutamide with Radium-223 Significantly Improves rPFS as First-Line Therapy for... August 27, 2025 Load more HOT NEWS One Year of Adjuvant T-DM1 Leads to Outstanding Long-Term Outcomes Among... Is there a future without Pap testing? 10 Things I Wish I Knew When I Was First Diagnosed... “After a fire and a pandemic, it felt amazing to finish...
